jetcityimage / iStockphoto.com
GSK has revealed plans to cut back on research and development (R&D), while Eli Lilly announced a plan to focus its R&D resources on oncology.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
GSK, Eli Lilly, research & development, R&D, innovation, cancer, drugs, pharmaceuticals, drug development